- Home
- KPTI vs IDN Comparison
KPTI vs IDN Comparison
Compare KPTI & IDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- IDN
- Stock Information
- Founded
- KPTI 2008
- IDN 1994
- Country
- KPTI United States
- IDN United States
- Employees
- KPTI N/A
- IDN N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- IDN Computer Software: Prepackaged Software
- Sector
- KPTI Health Care
- IDN Technology
- Exchange
- KPTI Nasdaq
- IDN Nasdaq
- Market Cap
- KPTI 51.7M
- IDN 46.8M
- IPO Year
- KPTI 2013
- IDN 1999
- Fundamental
- Price
- KPTI $7.36
- IDN $2.70
- Analyst Decision
- KPTI Strong Buy
- IDN Buy
- Analyst Count
- KPTI 5
- IDN 2
- Target Price
- KPTI $61.00
- IDN $3.00
- AVG Volume (30 Days)
- KPTI 101.5K
- IDN 57.3K
- Earning Date
- KPTI 05-12-2025
- IDN 05-13-2025
- Dividend Yield
- KPTI N/A
- IDN N/A
- EPS Growth
- KPTI N/A
- IDN N/A
- EPS
- KPTI N/A
- IDN N/A
- Revenue
- KPTI $145,237,000.00
- IDN $19,997,000.00
- Revenue This Year
- KPTI $4.87
- IDN $7.60
- Revenue Next Year
- KPTI $16.29
- IDN $10.02
- P/E Ratio
- KPTI N/A
- IDN N/A
- Revenue Growth
- KPTI N/A
- IDN 5.77
- 52 Week Low
- KPTI $3.51
- IDN $1.92
- 52 Week High
- KPTI $18.00
- IDN $4.46
- Technical
- Relative Strength Index (RSI)
- KPTI 68.69
- IDN 56.92
- Support Level
- KPTI $5.52
- IDN $2.47
- Resistance Level
- KPTI $6.56
- IDN $2.84
- Average True Range (ATR)
- KPTI 0.56
- IDN 0.16
- MACD
- KPTI 0.34
- IDN 0.03
- Stochastic Oscillator
- KPTI 86.12
- IDN 69.71
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.